Alexey_Fedoren
- Leerink Partners downgraded Gilead Sciences (GILD) to market perform from outperform as it sees headwinds in the growth of the HIV prophylaxis (PrEP) market.
- The investment bank downgraded its target price to $127 from $146 (~5% downside based on Monday’s close).
